Canada Markets open in 23 mins

Mydecine Innovations Group Inc. (MYCO.NE)

NEO - NEO Real Time Price. Currency in CAD
Add to watchlist
0.1950+0.0100 (+5.41%)
At close: 04:05PM EST
Full screen
Previous Close0.1850
Open0.1900
Bid0.1850 x N/A
Ask0.2000 x N/A
Day's Range0.1700 - 0.1950
52 Week Range0.1500 - 0.6800
Volume626,163
Avg. Volume665,616
Market Cap46.056M
Beta (5Y Monthly)4.50
PE Ratio (TTM)N/A
EPS (TTM)-0.2030
Earnings DateMay 18, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

    Dr. Saeid Babaei Appointed Independent Board Member as Mydecine Moves Closer to NASDAQ Listing in Q1 2022 DENVER, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has filed a full patent application covering multiple families of psilocin analogs. The application includes soluti

  • GlobeNewswire

    Mydecine Reports Third Quarter 2021 Financial Results and Provides Business Update

    --To Launch Phase 2/3 Smoking Cessation Clinical Trial with Johns Hopkins University (JHU) Signed 5-Year Research Agreement with JHU to Further Mydecine’s Research of Multiple Molecules for a Variety of Indications -- DENVER, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today reported its fin

  • GlobeNewswire

    Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021

    DENVER, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced that Dr. Rakesh Jetly, Chief Medical Officer of Mydecine, will be participating in a panel entitled, “The State of Care and the Case for Psychedelic Therapy” on Wednesday, November 10, 2021 at 7:30 p.m. on the eve of Veteran